Introduction {#S1}
============

Hepatitis B virus (HBV) infection is still a major challenge, especially in China, leading to unacceptable clinical outcomes e.g., chronic hepatitis B, liver cirrhosis, acute-on-chronic liver failure (ACLF), and hepatocellular carcinoma (HCC; [@B25]). Acute-on-chronic liver failure is an acute deterioration in liver function in the context of chronic liver disease with high mortality within 90 days ([@B10]; [@B37]; [@B13]). HBV-related ACLF (HBV-ACLF) makes up ∼90% of ACLF in China, which is becoming the major cause of HBV infection-related death ([@B36]). The outcome of HBV-ACLF is not satisfactory and is characterized by rapid and aggressive progression in different organs and systems. Despite decades of extensive research, the precise pathogenesis of HBV-ACLF remains unclear.

It has been reported that cell death in large numbers is a core event in the progression of liver diseases ([@B21]; [@B4]). Development of CHB is mainly due to persistent hepatic inflammation and hepatocyte death, including apoptosis and necrosis, which ultimately leads to liver failure ([@B19]; [@B3], [@B1],[@B2]). More recently a caspase-independent mode of programmed cell death, termed necroptosis, has been shown to be similar to apoptosis because of the tight regulation by distinct molecules, but it is also characterized by morphological features of necrosis ([@B8]; [@B11]; [@B5]). Receptor interacting protein kinase 3 (RIPK3; [@B11]; [@B39]) and mixed lineage kinase domain-like (MLKL) pseudokinase are the two key regulators in the development of necroptosis ([@B32]). Necroptosis is involved in the pathogenesis of inflammation-related diseases, such as inflammatory bowel disease ([@B24]), pancreatitis ([@B40]), and Gaucher disease ([@B35]). It is also reported that necroptosis plays a vital role in liver injury in animal models, including ethanol-induced liver injury ([@B27]) and acetaminophen-induced liver injury ([@B26]). However, this controversial finding is also reported by others in pancreatitis ([@B23]) and acetaminophen-induced liver injury studies ([@B7]).

Our current study aimed to investigate the involvement of necroptosis in HBV-ACLF.

Patients and Methods {#S2}
====================

Characteristics of Patients {#S2.SS1}
---------------------------

A total of 289 patients with chronic HBV infection (CHB) were identified from January 2015 to January 2018, retrospectively; whereas 70 healthy controls (HCs) were identified from July 2016 to March 2017 at the Department of Infectious Diseases, Ruijin Hospital, Shanghai, China. The total number subjects were divided into four groups: HBV-ACLF, non-ACLF without cirrhosis, non-ACLF with cirrhosis and HCs. The flow chart of patient enrollment is illustrated in [Figure 1](#F1){ref-type="fig"}.

![Flow chart of HBV-related patients in the present study.](fphys-11-00526-g001){#F1}

All HBV-ACLF patients were followed up with for at least 90 days to evaluate the short-term clinical outcomes. The primary endpoint of HBV-ACLF patients was categorized as survivor or non-survivor (underwent liver transplantation or death). CHB was identified as HBV mono-infected with positive hepatitis B surface antigen (HBsAg^+^) for at least 6 months prior to the enrollment in our current study ([@B34]). Diagnosis of cirrhosis in CHB was made according to at least one positive result from an ultrasonography, computed tomography, and magnetic resonance imaging.

The diagnostic criteria for HBV-ACLF was based on the consensus recommendations of the *Asian Pacific Association for the Study of the Liver* (APASL; [@B29]). Exclusion criteria included: patients with alcoholic liver diseases, non-alcoholic fatty liver diseases, congenital metabolic liver disease, autoimmune liver diseases, evidence of HCC, or age \>80 years. In the present study the APASL diagnostic criteria applied for ACLF was due to its suitability for Asians, especially for Chinese ACLF patients. The HBV-ACLF patients were managed according to the APASL consensus recommendations ([@B29]).

The present study is in accordance with the Declaration of Helsinki, and has been approved by the Human Ethics Committee, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from the participates.

Laboratory Assay {#S2.SS2}
----------------

Serum biochemical markers included pre-albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, and creatinine and the international normalized ratio (INR) was routinely measured. Serum HBsAg and hepatitis e antigen (HBeAg) were determined, using commercial enzyme immunoassay kits (AXSYM System; Abbott, Wiesbaden, Germany). The serum HBV DNA level was quantified, using Applied Biosystems PCR system (Prism 7500; Applied Biosystems, Inc., United States), with a lower limit of quantification at 500 IU/mL. All of these measurements were performed routinely by professional technicians at our hospital.

The following formula was used to calculate the Model of end-staged liver disease (MELD) score ([@B14]): MELD = 9.57 × LnCreatinine\[mg/dL\] + 3.78 × LnTotal bilirubin\[mg/dL\] + 11.2 × LnINR.

Measurement of Serum RIPK3 Level {#S2.SS3}
--------------------------------

Blood samples were collected from patients at enrollment. Serum was separated and stored in −20°C. RIPK3 was measured using a human RIPK3 ELISA kit (CUSABIO, Wuhan, China) ([@B20]; [@B33]; [@B30]; [@B31]) following the instructions from the manufacturer.

Immunohistochemistry and Quantification {#S2.SS4}
---------------------------------------

Among 23 liver tissues, 10 were from CHB patients undergoing liver biopsies, 8 were from HBV-ACLF patients undergoing liver transplantation and 5 were from healthy liver transplant donors during surgical procedures. Immunohistochemical staining for RIPK3 (Abcam, \#ab194699) and MLKL (Abcam, \#ab194699) were performed in these 23 liver tissues, according to the experiment protocol as previously described ([@B16]). Both RIPK3 and MLKL antibodies used for immunohistochemical staining in our study were carefully selected based on applicability, specificity, and also upon validation from other investigators ([@B22]; [@B38]; [@B28]; [@B41]). A negative control was coupled with the test in which the antibody was substituted by the primary rabbit negative control. The expression of RIPK3 or MLKL was objectively quantified using Image-Pro Plus 7.5 software followed by a macro by presetting the threshold in 10 random fields (400) per stained section. Data were expressed as relative mean density.

Statistics {#S2.SS5}
----------

Data are presented as the mean ± SD (standard deviation) or medians (25th, 75th percentile) as appropriate. For normally distributed data, an independent-sample t test was used when comparing two groups. For abnormally distributed data, non-parametric statistics were performed, and a Mann--Whitney *U* test was used when comparing two groups. When comparing categorical factors, Chi-square tests were performed. Spearman rank correlation analyses were performed to determine the co-efficient. To evaluate the prognostic value of the combination of RIPK3 and MELD score, we established a novel equation obtained by binary logistic regression as follows: RIPK3-MELD = 0.172 × MELD + 0.001 × RIPK3 − 4.484. A two-tailed *p* \< 0.05 was considered statistically significant.

All statistical analyses were performed using SPSS 17.0 statistical software (SPSS Inc, Chicago, IL, United States) and GraphPad Prism 6 (Graph- Pad Software, San Diego, CA, United States).

Results {#S3}
=======

Clinical Characteristics {#S3.SS1}
------------------------

Patient characteristics of all the study subjects are enumerated in [Table 1](#T1){ref-type="table"}. The four groups were clinically different, as suggested by all the measured parameters. Compared to other groups, patients with ACLF had remarkably higher levels of liver injury parameters, including ALT, AST, and TB, but lower levels of PAB. Moreover, in serum creatinine, HBV-DNA and coagulation parameters, INR were significantly higher in ACLF than in cirrhotic patients without ACLF ([Table 1](#T1){ref-type="table"}). All these abnormalities in ACLF contributed to a significantly higher level of MELD score compared to patients without ACLF (27.7 ± 5.8 vs 12.1 ± 4.4, *p* \< 0.001).

###### 

Patient characteristics at enrollment across different study groups.

                                                  **Non-ACLF without**   **Non-ACLF with**                
  ----------------------------------- ----------- ---------------------- ------------------- ------------ ---------
  Male, *n* (%)                       28 (40)     54 (77)                25 (63)             77 (86)      \<0.001
  Age (years)                         40.515.6    41.614.5               54.912.1            49.411.7     \<0.001
  Pre-albumin (mg/L)                  266.235.3   255.534.8              84.529.7            56.628.5     \<0.001
  Alanine aminotransferase (IU/L)     21.57.8     21.98.1                44.841.2            460.5695.1   \<0.001
  Aspartate aminotransferase (IU/L)   19.96.6     27.016.1               62.855.5            359.8490.6   \<0.001
  Albumin (g/L)                       42.52.4     42.53.7                28.35.1             30.430.5     \<0.001
  Total bilirubin (μmol/L)            10.04.0     15.27.5                57.575.0            339.7170.6   \<0.001
  Creatinine (μmol/L)                 --          --                     67.013.3            84.046.7     0.048
  log~10~ HBV DNA (IU/mL)             --          2.60.5                 3.11.2              4.11.8       \<0.001
  International normalized ratio      --          --                     1.30.2              2.20.9       \<0.001
  MELD score                          --          --                     12.144.4            25.75.8      \<0.001

HC, healthy control, ACLF, acute-on-chronic liver failure, HBV, hepatitis B virus, MELD, model for end-stage liver disease.

Necroptosis Associated Proteins Were Increased in HBV-ACLF Patients {#S3.SS2}
-------------------------------------------------------------------

Serum RIPK3 was measured in our 200 HBV patients and 70 HCs ([Figure 2](#F2){ref-type="fig"}). Serum RIPK3 was undetectable in 94.3 or 92.9% of HCs or non-ACLF patients without cirrhosis, respectively ([Figure 2](#F2){ref-type="fig"}). Cirrhotic patients without ACLF were more likely to have detectable RIPK3, although the level was relatively low. A ∼15-fold higher serum RIPK3 in the HBV-ACLF group compared to those in cirrhotic patients without ACLF was observed (*p* \< 0.001; [Figure 2](#F2){ref-type="fig"}). Intrahepatic expression of RIPK3 (*p* \< 0.01) and MLKL (*p* \< 0.001) with immunohistochemistry staining were both significantly higher in patients with HBV-ACLF than those from CHB patients ([Figure 3](#F3){ref-type="fig"}).

![Serum RIPK3 in healthy controls and HBV patients with and without ACLF.](fphys-11-00526-g002){#F2}

![Histopathology of liver tissues with H&E staining from donors (*n* = 5) **(A)**, CHB (*n* = 10) **(B)**, HBV-ACLF (*n* = 8) **(C)** patients (100×). Representative immunohistochemical micrographs of hepatic RIPK3 **(D--F)** and MLKL **(G--I)** in liver tissues of CHB, HBV-ACLF patients and donors. Relative mean density of RIPK3 **(J)** or MLKL **(K)** in immunohistochemical staining was compared across the three groups. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fphys-11-00526-g003){#F3}

Serum RIPK3 Was Correlated With Laboratory Markers of Severity of Liver Disease {#S3.SS3}
-------------------------------------------------------------------------------

The correlation between serum RIPK3 and routine laboratory markers was assessed ([Figure 4](#F4){ref-type="fig"}). A positive correlation was observed between serum RIPK3 and ALT or AST (*p* \< 0.0001; [Figures 4A,B](#F4){ref-type="fig"}). Serum RIPK3 was also correlated with a severity score of liver disease, MELD score including its parameters TB and INR, but not with serum creatinine (*p* \< 0.05; [Figures 4C--F](#F4){ref-type="fig"}).

![Correlation between serum RIPK3 with ALT **(A)**, AST **(B)**, TB **(C)**, INR **(D)**, Creatinine **(E)**, and MELD score **(F)**.](fphys-11-00526-g004){#F4}

Serum RIPK3 Were Higher in HBV-ACLF Survivors Than in HBV-ACLF Non-survivors {#S3.SS4}
----------------------------------------------------------------------------

Characteristics of ACLF patients at enrollment were compared between survivors and non-survivors ([Table 2](#T2){ref-type="table"}). Serum total bilirubin, INR and MELD scores were significantly higher in non-survivors than in survivors (all *p* \< 0.001). Furthermore, serum in RIPK3 in HBV-ACLF survivors and non-survivors were compared at 90 days. Serum PIPK3 in the non-survivors was 1.9-fold higher than that in the survivors at 90 days (*p* = 0.002, [Figure 5A](#F5){ref-type="fig"}). The prognostic analysis demonstrated that the area under the receiver operating curve (AUROC) of RIPK3 in the prediction of 90-day mortality was 0.715 (*p* \< 0.05), which was similar to that of the MELD score (0.763, *p* \< 0.05; [Figure 5B](#F5){ref-type="fig"}). The combined use of RIPK3 and MELD scores could further increase the AUROC to 0.80 ([Figure 5B](#F5){ref-type="fig"}).

###### 

Baseline patient characteristics in ACLF group according to survival status.

                                      **Survivor**   **Non-survivor**   
  ----------------------------------- -------------- ------------------ ----------
  Male, *n* (%)                       27 (82)        51 (88)            ns
  Age (years)                         48.110.2       50.112.5           ns
  Pre-albumin (mg/L)                  60.534.5       54.324.4           ns
  Alanine aminotransferase (IU/L)     591.9858.3     384.4575.1         ns
  Aspartate aminotransferase (IU/L)   369.4494.9     354.3492.4         ns
  Albumin (g/L)                       28.75.9        31.438.2           ns
  Total bilirubin (μmol/L)            247.3116.4     393.2174.8         \<0.0001
  Creatinine (μmol/L)                 73.416.9       90.156.5           ns
  log~10~ HBV DNA (IU/mL)             4.01.9         4.11.8             ns
  International normalized ratio      1.80.4         2.41.0             0.0005
  MELD score                          22.43.6        27.56.1            \<0.0001

ACLF, acute-on-chronic liver failure, HBV, hepatitis B virus, MELD, model for end-stage liver disease.

![Serum RIPK3 in survivors and non-survivors of HBV-ACLF patients at 90 days **(A)** Sensitivity and specificity for serum RIPK3, MELD score and combination of serum RIPK3 plus MELD score for predicting 90 days' mortality of HBV-ACLF patients **(B)**. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fphys-11-00526-g005){#F5}

Discussion {#S4}
==========

ACLF is a life-threatening clinical syndrome with extremely high mortality ([@B9]); yet much is unknown about the pathogenesis of ACLF. Due to the alteration of intestinal flora, intestinal endotoxin accumulates massively during the development of ACLF, leading to secretion of pro-inflammation cytokines ([@B15]; [@B18]), which subsequently induce various types of cell death.

In our present study, elevated, circulating, and hepatic RIPK3 were correlated with the severity of HBV-related liver diseases, i.e., 90-day mortality. The original source of the elevated serum RIPK3 might derive from damaged hepatocytes, as suggested by the significantly increased hepatic expression of RIPK3 in HBV-ACLF patients. This scenario is consistent with the massive hepatocyte death detected in HBV-ACLF patients ([@B17]). Elevated hepatic RIPK3 might leak from the damaged hepatocytes and subsequently into the circulation. The elevation of RIPK3 might suggest a potential contribution of RIPK3 to necroptosis in HBV-ACLF, due to the involvement of necroptosis in the pathogenesis of inflammation-related diseases ([@B40]; [@B24]) and various liver injury models ([@B26]; [@B27]). However, there is a controversial report on necroptosis in liver diseases, showing that RIPK3 is minimally expressed in the damaged hepatocytes and is not indispensable for the activation of hepatocyte necroptosis ([@B6]). Although we are not able to confirm the role of necroptosis in the pathogenesis of ACLF in the current study, we observed that there was a significantly elevated expression of MLKL in the liver of HBV-ACLF patients. MLKL is the downstream protein of RIPK3, acting as an executor of necroptosis. We acknowledge that the increase of RIPK3 or MLKL expression does not reflect the activation of the necroptosis pathway directly, which should be confirmed with the phosphorylation status of both RIPK3 and MLKL. It is currently difficult to detect phosphorylated RIPK3 and MLKL using commercially available antibodies. The precise role of necroptosis in the pathogenesis of ACLF remains to be explored in future studies.

Acute-on-chronic liver failure is a syndrome characterized by acute hepatic decompensation, resulting in liver failure (jaundice and prolongation of the INR). One or more extrahepatic organ failures is/are associated with increased mortality within a period of 28 days and up to 3 months from onset. It has been reported that the mortality of ACLF patients increases sharply within a period of 28 and 90 days ([@B12]). Importantly, our current study demonstrated that serum RIPK3 was able to differentiate between survivors and non-survivors of HBV-ACLF patients at 90 days, i.e., higher serum RIPK3 correlated with a higher number of non-survivors, suggesting that necroptosis contributes to the development of HBV-ACLF which is associated with poor outcomes. This is supported by the positive correlation between serum RIPK3 and MELD scores in our current study, which reflects the severity of HBV-ACLF. In addition, the prognostic accuracy of RIPK3 was similar to the MELD score in predicting 90-day mortality and was significantly increased by the combined use of RIPK3 and MELD. The result was in line with the previous findings in general ICU patients, showing that elevated plasma RIPK3 is associated with organ failure and death ([@B20]).

Serum RIPK3 in our study was assessed using an established commercial assay that has also been used to investigate necroptosis in sepsis ([@B20]; [@B33]; [@B30]; [@B31]). However, it has not been established, beyond a doubt, what is measured in these assays, which means that specific reagents for RIPK3 are not available in the liver and serum. Therefore, it should be interpreted with caution before a well validated assay for serum RIPK3 is fully established. Another limitation of our study is that paired serum and liver tissue samples were not available in our study. Consequently, we were not able to perform a correlation analysis between the circulating level of RIPK3 and hepatic expression of RIPK3. We acknowledge this as a limitation of our study, particularly the phosphorylation of both RIPK3 and MLKL in these patients, but we were not able to clarify this point in the current study. It would be interesting to see whether serum levels of RIPK3 are associated with lactate dehydrogenase, which is a marker of cell necrosis. However, lactate dehydrogenase is not routinely examined in our hospitalized patients. Thus, we are not able to retrospectively perform such tests in the current study but it will be determined in a future study.

Conclusion {#S5}
==========

Circulating RIPK3 was significantly increased in patients with HBV-ACLF and was associated with a clinical outcome. The improved combined objective scores can offer additional prognostic value in ACLF patients for physicians with more accurate expectations.
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